Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11502461rdf:typepubmed:Citationlld:pubmed
pubmed-article:11502461lifeskim:mentionsumls-concept:C0025266lld:lifeskim
pubmed-article:11502461lifeskim:mentionsumls-concept:C0029456lld:lifeskim
pubmed-article:11502461lifeskim:mentionsumls-concept:C0376358lld:lifeskim
pubmed-article:11502461lifeskim:mentionsumls-concept:C0678226lld:lifeskim
pubmed-article:11502461lifeskim:mentionsumls-concept:C0279492lld:lifeskim
pubmed-article:11502461pubmed:issue2 Suppl 1lld:pubmed
pubmed-article:11502461pubmed:dateCreated2001-8-14lld:pubmed
pubmed-article:11502461pubmed:abstractTextThe frequency of osteoporotic fractures is greatly increased in men receiving androgen deprivation therapy (ADT), but whether the risk of osteoporosis differs between different types of ADT or between continuous and intermittent therapy has not been determined. Techniques for modifying ADT-associated bone loss have not been clearly identified.lld:pubmed
pubmed-article:11502461pubmed:languageenglld:pubmed
pubmed-article:11502461pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11502461pubmed:citationSubsetIMlld:pubmed
pubmed-article:11502461pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11502461pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11502461pubmed:statusMEDLINElld:pubmed
pubmed-article:11502461pubmed:monthAuglld:pubmed
pubmed-article:11502461pubmed:issn1527-9995lld:pubmed
pubmed-article:11502461pubmed:authorpubmed-author:DaniellH WHWlld:pubmed
pubmed-article:11502461pubmed:issnTypeElectroniclld:pubmed
pubmed-article:11502461pubmed:volume58lld:pubmed
pubmed-article:11502461pubmed:ownerNLMlld:pubmed
pubmed-article:11502461pubmed:authorsCompleteYlld:pubmed
pubmed-article:11502461pubmed:pagination101-7lld:pubmed
pubmed-article:11502461pubmed:dateRevised2005-11-17lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:meshHeadingpubmed-meshheading:11502461...lld:pubmed
pubmed-article:11502461pubmed:year2001lld:pubmed
pubmed-article:11502461pubmed:articleTitleOsteoporosis due to androgen deprivation therapy in men with prostate cancer.lld:pubmed
pubmed-article:11502461pubmed:affiliationDepartment of Family Practice, University of California School of Medicine at Davis, California, USA.lld:pubmed
pubmed-article:11502461pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11502461pubmed:publicationTypeReviewlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11502461lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11502461lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11502461lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11502461lld:pubmed